You’re using a public version of DrugPatentWatch with 5 free searches available | Register to unlock more free searches. CREATE FREE ACCOUNT

Last Updated: March 29, 2024

Details for Patent: 10,793,547


✉ Email this page to a colleague

« Back to Dashboard


Summary for Patent: 10,793,547
Title:Modulator of the cystic fibrosis transmembrane conductance regulator, pharmaceutical compositions, methods of treatment, and process for making the modulator
Abstract: Compounds of Formula (I): ##STR00001## pharmaceutically acceptable salts thereof, deuterated derivatives of any of the foregoing, and metabolites of any of the foregoing are disclosed. Pharmaceutical compositions comprising the same, methods of treating cystic fibrosis using the same, and methods for making the same are also disclosed. Also disclosed are solid state forms of Compound 1 and salts and solvates thereof.
Inventor(s): Abela; Alexander Russell (San Diego, CA), Alcacio; Timothy (San Diego, CA), Anderson; Corey (San Diego, CA), Angell; Paul Timothy (Carlsbad, CA), Baek; Minson (San Diego, CA), Clemens; Jeremy J. (San Diego, CA), Cleveland; Thomas (San Marcos, CA), Ferris; Lori Ann (Wilmington, MA), Grootenhuis; Peter Diederik Jan (Del Mar, CA), Gross; Raymond Stanley (Poway, CA), Gulevich; Anton V. (San Diego, CA), Hadida Ruah; Sara Sabina (La Jolla, CA), Hsia; Clara Kuang-Ju (San Diego, CA), Hughes; Robert M. (San Diego, CA), Joshi; Pramod Virupax (San Diego, CA), Kang; Ping (San Diego, CA), Keshavarz-Shokri; Ali (San Diego, CA), Khatuya; Haripada (San Diego, CA), Krenitsky; Paul John (San Diego, CA), McCartney; Jason (Cardiff by the Sea, CA), Miller; Mark Thomas (San Diego, CA), Paraselli; Prasuna (San Diego, CA), Pierre; Fabrice Jean Denis (La Jolla, CA), Shi; Yi (Natick, MA), Shrestha; Muna (Belmont, MA), Siesel; David Andrew (San Diego, CA), Stavropoulos; Kathy (Quincy, MA), Termin; Andreas P. (Encinitas, CA), Van Goor; Fredrick F. (San Diego, CA), Uy; Johnny (San Diego, CA), Young; Timothy John (San Diego, CA), Zhou; Jinglan (San Diego, CA)
Assignee: Vertex Pharmaceuticals Incorporated (Boston, MA)
Application Number:15/836,627
Patent Claim Types:
see list of patent claims
Use; Composition; Compound;

Drugs Protected by US Patent 10,793,547

Applicant Tradename Generic Name Dosage NDA Approval Date TE Type RLD RS Patent No. Patent Expiration Product Substance Delist Req. Patented / Exclusive Use Submissiondate
Vertex Pharms Inc TRIKAFTA (COPACKAGED) elexacaftor, ivacaftor, tezacaftor; ivacaftor GRANULES;ORAL 217660-001 Apr 26, 2023 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO ⤷  Try a Trial
Vertex Pharms Inc TRIKAFTA (COPACKAGED) elexacaftor, ivacaftor, tezacaftor; ivacaftor GRANULES;ORAL 217660-002 Apr 26, 2023 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 2 TO ⤷  Try a Trial
Vertex Pharms Inc TRIKAFTA (COPACKAGED) elexacaftor, ivacaftor, tezacaftor; ivacaftor TABLET;ORAL 212273-002 Jun 8, 2021 RX Yes No ⤷  Try a Trial ⤷  Try a Trial Y Y TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR ⤷  Try a Trial
Vertex Pharms Inc TRIKAFTA (COPACKAGED) elexacaftor, ivacaftor, tezacaftor; ivacaftor TABLET;ORAL 212273-001 Oct 21, 2019 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 12 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR ⤷  Try a Trial
Vertex Pharms Inc TRIKAFTA (COPACKAGED) elexacaftor, ivacaftor, tezacaftor; ivacaftor TABLET;ORAL 212273-001 Oct 21, 2019 RX Yes Yes ⤷  Try a Trial ⤷  Try a Trial Y Y TREATMENT OF CYSTIC FIBROSIS IN PATIENTS AGED 6 YEARS AND OLDER WHO HAVE AT LEAST ONE F508DEL MUTATION IN THE CFTR GENE OR A MUTATION IN THE CFTR GENE THAT IS RESPONSIVE BASED ON IN VITRO DATA WITH ELEXACAFTOR, TEZACAFTOR, AND IVACAFTOR ⤷  Try a Trial
>Applicant >Tradename >Generic Name >Dosage >NDA >Approval Date >TE >Type >RLD >RS >Patent No. >Patent Expiration >Product >Substance >Delist Req. >Patented / Exclusive Use >Submissiondate

International Family Members for US Patent 10,793,547

Country Patent Number Estimated Expiration Supplementary Protection Certificate SPC Country SPC Expiration
Argentina 110346 ⤷  Try a Trial
Australia 2017371200 ⤷  Try a Trial
Australia 2021211993 ⤷  Try a Trial
Australia 2023203944 ⤷  Try a Trial
Brazil 112019011626 ⤷  Try a Trial
>Country >Patent Number >Estimated Expiration >Supplementary Protection Certificate >SPC Country >SPC Expiration

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.